Clinical Trials Directory

Trials / Completed

CompletedNCT03065868

Effect of H. Pylori Eradication on the Fate of H. Pylori-associated Gastric Polyp

Effect of H. Pylori Eradication on the Fate of H. Pylori-associated Gastric Polyp (Randomized Controlled Study)

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
32 (actual)
Sponsor
Kyungpook National University Hospital · Academic / Other
Sex
All
Age
20 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Evaluation of the effect of H. pylori eradication on regression of H. pylori-related gastric polyp (Ranomized controlled trial) 1. Study design: open labeled RCT 2. Study group H. pylori eradication group (N=17), non-eradication group (N=15) 3. Treatment plan 1. Baseline EGD : 0.3-1cm sized polyp - bx \& CLO test (antrum \& body) ==\> if H. pylori positive and eligible patients, randomization 2. Triple therapy 3. UBT (4week after eradication) 4. Follow-up EGD: gross finding, CLO test 4. Evaluation of polyp regression 1. disappear 2. regression over 50% (size, number) 3. no change or increase (size, number)

Detailed description

(A) Study population 1. inclusion HP-realetd polyp polyp size with 0.3cm-1cm 20 yr - 70yr 2. exclusion peptic ulcer, healing stage or acute stage recent use of PPI within 4weeks Liver cirrhosis, renal insufficiency, other serious chronic or acute disease current infection of other bacteria, virus, or fungus cancer, psychologic disease heavy drinker drug abuser pregnant women, Penicillin allergy, digoxin, antifungal, wafarin previosu H. pylori eradication enroll gastric polyp with bleeding or malignant transformation tiny polyp less than 3mm. (B) Study method 1. Study design: open labeled RCT 2. Study group H. pylori eradication group (N=17), non-eradication group (N=15) 3. Treatment plan 1. Baseline EGD: 0.3-1cm sized polyp - bx \& CLO test (antrum \& body) ==\> if H. pylori positive and eligible patients, randomization 2. Triple therapy 3. UBT (4week after eradication) if eradication failure in triple therapy, 2nd line treatment (metroniazole based quadraple therpay) and the UBT (4week after eradication) 4. Follow-up EGD (3-9M): gross finding, CLO test 4. Evaluation of polyp regression 1. disappear 2. regression over 50% (size, number) 3. no change or increase (size, number) 5. Statistical analysis 1. Chi-square test to compare polyp regression between treatment \& control group. 2. t-test to compare continuous variables between treatment \& control group. 3. Paired T-test to compare the size between baseline and follow-up EGD. 4. Regression analysis: univariate \& multivariate analysis.

Conditions

Interventions

TypeNameDescription
DRUGH. pylori eradication (Amoxaxillin, Lanston, Clarithromycin)H. pylori eradication (Triple Therapy) as first line treatment if eradication failure, quadruple therpy will be provided as 2nd line treatment

Timeline

Start date
2015-12-09
Primary completion
2019-04-30
Completion
2019-04-30
First posted
2017-02-28
Last updated
2019-09-26

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT03065868. Inclusion in this directory is not an endorsement.